Keros Therapeutics, Inc. (KROS): Total Liabilities
$34.89M
As of 2025-12-31
$25.28M
As of 2026-06-30
+5.9%
3-year compound annual growth
+35.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $34.89M | -21.3% | 2026-03-04, Balance as of period end |
| 2024-12-31 | $44.33M | +17.2% | 2026-03-04, Balance as of period end |
| 2023-12-31 | $37.81M | +28.8% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $29.36M | +143.1% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $12.08M | +56.4% | 2023-03-03, Balance as of period end |
| 2020-12-31 | $7.72M | -26.2% | 2022-03-09, Balance as of period end |
| 2019-12-31 | $10.46M | n/a | 2021-03-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $34.89M | -21.3% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $343.95M | +27.5% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $362.11M | -9.9% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $85.96M | -29.1% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $284.00M | -46.4% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $543.42M | +388.1% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $509.73M | +128.3% |
| Harrow, Inc. (HROW) | 2025-12-31 | $347.39M | +8.7% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $86.39M | +33.0% |
Compare KROS, AKBA, SDGR, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗